Zynex Dirección

Dirección controles de criterios 4/4

El CEO de Zynex's es Thomas Sandgaard , nombrado en Jan 1996, tiene una permanencia de 28.25 años. compensación anual total es $1.22M, compuesta por 53.4% salario y 46.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 50.23% de las acciones de la empresa, por valor de $178.67M. La antigüedad media del equipo directivo y de la junta directiva es de 3.4 años y 6.3 años, respectivamente.

Información clave

Thomas Sandgaard

Chief Executive Officer (CEO)

US$1.2m

Compensación total

Porcentaje del salario del CEO	53.4%
Permanencia del CEO	28.3yrs
Participación del CEO	50.2%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

May 03

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Mar 03

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Sep 21

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Aug 02

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Aug 01

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Jul 25

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Jul 12

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Jul 11

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?

Apr 13

Zynex (NASDAQ:ZYXI) Seems To Use Debt Quite Sensibly

Mar 23

Zynex: Letter Indicates UnitedHealthcare Is Terminating Contract - An Undisclosed Loss Accounting For 50%+ EBITDA

Feb 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Thomas Sandgaard en comparación con los beneficios de Zynex?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$8m
Dec 31 2023	US$1m	US$650k	US$10m
Sep 30 2023	n/a	n/a	US$16m
Jun 30 2023	n/a	n/a	US$17m
Mar 31 2023	n/a	n/a	US$17m
Dec 31 2022	US$1m	US$575k	US$17m
Sep 30 2022	n/a	n/a	US$18m
Jun 30 2022	n/a	n/a	US$20m
Mar 31 2022	n/a	n/a	US$19m
Dec 31 2021	US$988k	US$496k	US$17m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$5m
Mar 31 2021	n/a	n/a	US$5m
Dec 31 2020	US$1m	US$480k	US$9m
Sep 30 2020	n/a	n/a	US$10m
Jun 30 2020	n/a	n/a	US$11m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	US$527k	US$480k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$10m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	US$1m	US$480k	US$10m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	US$10m
Mar 31 2018	n/a	n/a	US$9m
Dec 31 2017	US$808k	US$398k	US$7m

Compensación vs. Mercado: La compensación total de Thomas($USD1.22M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD2.37M).

Compensación vs. Ingresos: La compensación de Thomas ha sido consistente con los resultados de la empresa en el último año.

CEO

Thomas Sandgaard (64 yo)

28.3yrs

Permanencia

US$1,217,895

Compensación

Mr. Thomas Sandgaard founded Zynex, Inc. in 1996 and has been its Chairman, Chief Executive Officer and President since 1996. Mr. Sandgaard served as the Chief Financial Officer and Chief Accounting Office...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Sandgaard	Founder	28.3yrs	US$1.22m	50.23% $ 184.2m
Daniel Moorhead	Chief Financial Officer	6.9yrs	US$883.15k	0.17% $ 605.3k
Anna Lucsok	Chief Operating Officer	3.3yrs	US$714.40k	0.11% $ 417.2k
Steve Fox	Vice President Of Sales	no data	sin datos	sin datos
Donald Gregg	President of Zynex Monitoring Solutions	1.3yrs	sin datos	sin datos
Neil Friery	President & COO of Zynex Monitoring Solutions	3.5yrs	sin datos	sin datos

3.5yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ZYXI se considera experimentado (3.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Sandgaard	Founder	28.3yrs	US$1.22m	50.23% $ 184.2m
Barry Michaels	Independent Director	6.3yrs	US$159.70k	0.20% $ 716.8k
Michael Cress	Independent Director	6.3yrs	US$154.70k	0.20% $ 716.8k
Joshua Disbrow	Independent Director	6.2yrs	US$154.70k	0.20% $ 716.8k

6.3yrs

Permanencia media

64.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ZYXI se considera experimentada (6.3 años de antigüedad promedio).

Zynex Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Zynex, Inc., Annual General Meeting, May 16, 2024

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Insufficient new directors

Recent updates

Earnings Update: Here's Why Analysts Just Lifted Their Zynex, Inc. (NASDAQ:ZYXI) Price Target To US$19.88

Zynex, Inc. Provides Earnings Guidance for the Second Quarter of 2024 and Reaffirms for the Full Year 2024

Price target increased by 8.1% to US$19.88

First quarter 2024 earnings released: EPS: US$0 (vs US$0.043 in 1Q 2023)

Zynex, Inc. to Report Q1, 2024 Results on Apr 30, 2024

Zynex, Inc., Annual General Meeting, May 16, 2024

Consensus EPS estimates fall by 11%

Earnings Miss: Zynex, Inc. Missed EPS By 33% And Analysts Are Revising Their Forecasts

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zynex, Inc. Provides Earnings Guidance First Quarter and Full Year 2024

Zynex, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Zynex, Inc. Introduces New Products

Zynex, Inc. Receives FDA Clearance for its Next Generation NMES Device

Why Investors Shouldn't Be Surprised By Zynex, Inc.'s (NASDAQ:ZYXI) P/E

Zynex, Inc. Submits FDA Application for Its NMES Device

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $20 million worth of its shares.

Zynex, Inc. Provides Earnings Guidance for Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Price target decreased by 24% to US$16.50

Investor sentiment deteriorates as stock falls 15%

Zynex, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Now 23% undervalued after recent price drop

Now 22% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Now 23% undervalued after recent price drop

Chief Financial Officer recently sold US$170k worth of stock

Chief Financial Officer notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 16%

Is Zynex (NASDAQ:ZYXI) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$24.00

Zynex, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Zynex, Inc. Confirms Earnings Guidance for the Second Quarter of 2023 and Reiterates Earnings Guidance for the Full Year 2023

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Investor sentiment improves as stock rises 30%

Are Investors Undervaluing Zynex, Inc. (NASDAQ:ZYXI) By 43%?

Full year 2022 earnings: EPS exceeds analyst expectations

Investor sentiment deteriorates as stock falls 24%

Should You Be Adding Zynex (NASDAQ:ZYXI) To Your Watchlist Today?

Zynex, Inc. Reaffirms Earnings Guidance for the Fourth Quarter and Full Year 2022

Now 25% undervalued

Insufficient new directors

Chief Financial Officer recently sold US$407k worth of stock

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

Third quarter 2022 earnings: EPS exceeds analyst expectations

Zynex, Inc. Provides Revenue Guidance for the Fourth Quarter 2022

Zynex, Inc. to Report Q3, 2022 Results on Oct 27, 2022

Zynex, Inc. Re-Iterates Earnings Guidance for the Full Year 2022

Short Squeeze Candidate With Low PEG Ratio: Zynex

Zynex, Inc. Begins Enrollments in Large-Scale Blood Loss Detection Clinical Trial with its Second-Generation Monitoring System, CM-1600

Zynex begins enrollment in blood loss detection trial for CM-1600 monitoring system

Zynex, Inc. Announces First Enrollments in Apheresis Donation Clinical Trial with Second Generation Fluid Monitoring System

These 4 Measures Indicate That Zynex (NASDAQ:ZYXI) Is Using Debt Safely

Zynex Cures The Pain Of Its Shareholders: Q2 Results

Zynex, Inc. Provides Revenue Guidance for the Third Quarter of 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Zynex: Upside Looks Well Priced In, Efficiency Headwinds Remain

Zynex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Zynex, Inc. Reiterates Revenue Guidance Full Year 2022

Is Zynex, Inc. (NASDAQ:ZYXI) Trading At A 46% Discount?

Zynex June and Q2 orders hit all-time high, re-affirms Q2 and FY22 guidance

Investor sentiment improved over the past week

Zynex, Inc. (NasdaqGS:ZYXI) announces an Equity Buyback for $10 million worth of its shares.

First quarter 2022 earnings: EPS misses analyst expectations

Insufficient new directors

Zynex, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Is It Time To Consider Buying Zynex, Inc. (NASDAQ:ZYXI)?